Ove Öhman

Empowering communities with affordable AI-based diagnostics to to improve global health equity

SampleFacts technology is based upon research carried out by Professor Ulf Landegren and Dr Johan Björksten at Uppsala University. Our vision is to develop intuitive devices that can eliminate barriers often associated with blood sample collection as performed during research, pre-clinical and clinical studies and, ultimately, for applications in the healthcare market. The SampleFacts company was founded in 2023 and is headquartered in Uppsala, Sweden.

Jag som jobbar på Stormpenna skriver på en fantasyserie om den unga kvinnan Helmi vars liv ställs upp och ner, samt illustrerar som en del i processen.

Sysmex Astrego is a rapidly growing in vitro diagnostic company based in Uppsala, Sweden. The company was founded as Astrego Diagnostics in March 2017 and was acquired by Sysmex Corporation, Japan, in May 2022 when the new entity Sysmex Astrego AB was formed. The company name comes from Antibiotic Susceptibility Testing – AST, and rego – being latin for guide, steer or manage. Our mission is to help in the global fight against antimicrobial resistance (AMR) and our products are designed to guide physicians in the selection of effective antibiotic treatments to improve patient outcomes and make antibiotic stewardship easy. Our team combines multidisciplinary scientific excellence with seasoned entrepreneurs and diagnostic industry management.

Rarity Bioscience provides ultrasensitive multiplex assays for mutation detecting in blood and other liquid biopsies for research, pharma and clinics. The sensitivity of our precision diagnostics technology enables patient stratification, treatment choice & monitoring, early MRD and relapse detection and post-transplantation follow-up for optimized cancer care. It also enables refined inclusion stratification and monitoring in clinical trials. The company was founded 2021 based on a discovery by Dr Lei Chen, PhD in molecular biology and a member of Professor Ulf Landegrens team at the Department of Immunology, Genomics and Pathology at Uppsala University.

Moleculent’s platform detects cell-cell interactions directly within their native tissue environment. This makes it possible to see how healthy cells function, how diseased cells differ, and provides access to functional proteomics at scale. #cellcellcommunication

SpinChip Diagnostics is a medical device company that is developing a game changing and proprietary platform for in vitro diagnostics point of care analyses. The platform will make it possible to perform a broader range of analyses using one platform and to transfer analyses from central laboratories to point of care without loss in quality. All analyses are performed within a few minutes based on a fraction of a droplet of blood and at a unit cost significantly lower than other point of care platforms.

Endovab's mission is to develop and provide innovative endovascular tools and techniques that improve vascular treatments through research and clinical experience. Endovab was founded in 2009 and has its head office in Stockholm and a research laboratory in Uppsala. The company’s founder and innovation lead MD, Ph.D. Krister Liungman, Head of Vascular Surgery at Uppsala University Hospital, has more than 25 years of experience in treating vascular disease. With experienced backers and a driven team, Endovab is committed to its objective of improving treatment within the field of endovascular surgery.

Empowering communities with affordable AI-based diagnostics to to improve global health equity

SampleFacts technology is based upon research carried out by Professor Ulf Landegren and Dr Johan Björksten at Uppsala University. Our vision is to develop intuitive devices that can eliminate barriers often associated with blood sample collection as performed during research, pre-clinical and clinical studies and, ultimately, for applications in the healthcare market. The SampleFacts company was founded in 2023 and is headquartered in Uppsala, Sweden.

Jag som jobbar på Stormpenna skriver på en fantasyserie om den unga kvinnan Helmi vars liv ställs upp och ner, samt illustrerar som en del i processen.

Sysmex Astrego is a rapidly growing in vitro diagnostic company based in Uppsala, Sweden. The company was founded as Astrego Diagnostics in March 2017 and was acquired by Sysmex Corporation, Japan, in May 2022 when the new entity Sysmex Astrego AB was formed. The company name comes from Antibiotic Susceptibility Testing – AST, and rego – being latin for guide, steer or manage. Our mission is to help in the global fight against antimicrobial resistance (AMR) and our products are designed to guide physicians in the selection of effective antibiotic treatments to improve patient outcomes and make antibiotic stewardship easy. Our team combines multidisciplinary scientific excellence with seasoned entrepreneurs and diagnostic industry management.